Nasdaq

Ivonescimab Plus Chemotherapy Demonstrates Consistent Global Benefit: HARMONi Data Update Shows OS HR=0.78, Nominal P=0.0332

The overall survival (OS) hazard ratio (HR) in the HARMONi trial was 0.78, with a nominal p-value of 0.0332 In the North American patients, the OS HR was 0.70 The HARMONi trial has already ...
ascopubs.org

Validity of Meta-Analytical Estimates and Hazard Ratios Quantifying Survival Benefit of Immunochemotherapy in Low PD-L1–Expressing Esophageal Squamous Cell Carcinoma

Wu et al 1 conducted an interesting study-level meta-analysis comparing the efficacy of PD-1 antibody plus chemotherapy with chemotherapy alone in patients with PD-L1–expressing esophageal squamous ...